Good Life Advisors LLC Sells 1,433 Shares of Stryker Co. (NYSE:SYK)

Good Life Advisors LLC lowered its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 38.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,331 shares of the medical technology company's stock after selling 1,433 shares during the quarter. Good Life Advisors LLC's holdings in Stryker were worth $868,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Norges Bank bought a new position in Stryker in the 4th quarter worth $1,710,744,000. GAMMA Investing LLC raised its holdings in Stryker by 43,226.8% in the 1st quarter. GAMMA Investing LLC now owns 2,074,922 shares of the medical technology company's stock worth $772,390,000 after acquiring an additional 2,070,133 shares during the period. Raymond James Financial Inc. bought a new position in Stryker in the 4th quarter worth $353,394,000. FMR LLC raised its holdings in Stryker by 10.0% in the 4th quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock worth $2,892,946,000 after acquiring an additional 727,850 shares during the period. Finally, Proficio Capital Partners LLC raised its holdings in Stryker by 52,520.8% in the 4th quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company's stock worth $214,660,000 after acquiring an additional 595,061 shares during the period. Institutional investors own 77.09% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Wall Street Zen upgraded shares of Stryker from a "hold" rating to a "buy" rating in a report on Saturday. Truist Financial lifted their target price on shares of Stryker from $390.00 to $400.00 and gave the stock a "hold" rating in a report on Monday, May 5th. BTIG Research set a $403.00 target price on shares of Stryker and gave the stock a "buy" rating in a report on Monday, April 14th. Citigroup restated a "buy" rating and issued a $455.00 price target (up from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Finally, Needham & Company LLC restated a "buy" rating and issued a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. Four research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, Stryker currently has a consensus rating of "Moderate Buy" and a consensus target price of $427.30.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares in the company, valued at $1,288,195,208.96. The trade was a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 5.90% of the company's stock.

Stryker Price Performance

Shares of Stryker stock opened at $377.05 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The firm's 50-day simple moving average is $373.53 and its 200-day simple moving average is $375.55. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The firm has a market cap of $143.91 billion, a P/E ratio of 48.59, a price-to-earnings-growth ratio of 2.93 and a beta of 0.91.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The business had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. During the same period in the previous year, the business earned $2.50 EPS. The firm's revenue was up 11.9% on a year-over-year basis. As a group, research analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.89%. Stryker's dividend payout ratio (DPR) is presently 45.41%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.